Jessica Merrill
Senior Editor
Latest From Jessica Merrill
Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.
Novartis Has A New Goal: $2bn Peak Sales Per Product
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
NYC’s Ambition: Be A Premier Biotech Hub
New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.
US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.
Obesity Stole The Q3 Show
Novo Nordisk’s Wegovy/Ozempic and Lilly’s Mounjaro were third quarter standouts, but the exploding obesity category was a theme across many of the big pharma company earnings calls.
Q32 Bio Resets As A Public Company With Two Mid-Stage Assets
The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.